TICKERNERD
Menu
MPLTMPLTHealthcare · Biotechnology

MPLT Stock Forecast: MapLight Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$11
+1.34% on the day

The 14 Wall Street analysts covering MapLight Therapeutics, Inc. hold a median 12-month price target of $25 — +120.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$519.9M
Ticker Nerd rank
10 / 100
Median analyst target
$25
Analysts covering
14
Revenue$0.0
Operating income−$64.5M
Net income−$60.7M
Free cash flow−$51.2M
Quarterly, 5 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−68.9%
YTD
−35.3%
From high
−71.5%
From low
+14.7%
$10
$40
Range since 27 Oct 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

MPLT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MapLight Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
10 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
53
Size
52
Issuance
44
Accruals
42
Quality
27
Value
24
Growth
8
Volatility
4
Momentum
2

Revisions (53): Analysts have, on balance, been raising their forecasts.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MPLT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MPLT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 27 Oct 2025Adjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26MPLTHigh $45Median $25Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $13Median $25High $45

The green dot is the last close — the median target sits +120.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
10 Aug 2026UBSDowngradeNeutral$52 → $13
28 July 2026Canaccord GenuityMaintainsBuy—
28 July 2026Canaccord GenuityMaintainsBuy$43 → $24
28 July 2026HC Wainwright & Co.MaintainsBuy—
28 July 2026HC Wainwright & Co.MaintainsBuy$45 → $26
28 July 2026Morgan StanleyDowngradeEqual-Weight—
28 July 2026Morgan StanleyDowngradeEqual-Weight$34 → $21
25 July 2026Canaccord GenuityMaintainsBuy—
24 July 2026Canaccord GenuityMaintainsBuy$35 → $43
21 July 2026BMO CapitalInitiatesOutperform$46
21 July 2026BMO CapitalInitiatesOutperform—
21 July 2026UBSMaintainsBuy—
21 July 2026UBSMaintainsBuy$48 → $52
10 July 2026NeedhamMaintainsBuy$42 → $45
10 July 2026NeedhamMaintainsBuy—
25 June 2026Raymond JamesInitiatesStrong Buy—
23 June 2026Craig-HallumMaintainsBuy—
22 June 2026NeedhamMaintainsBuy—
2 June 2026StifelMaintainsBuy—
28 May 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MPLT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MPLT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MPLT vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26MPLTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MPLT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

MapLight Therapeutics, Inc. (MPLT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 58% of US stocks

EV / EBITDA
−0.9×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−111.5%

Higher than 12% of US stocks

Return on assets
−67.1%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MapLight Therapeutics, Inc. (MPLT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MapLight Therapeutics, Inc. has a market value of $519.9M and an enterprise value of $217.2M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$190.9M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$151.8M, after $537K of capital spending.

  • Shares outstanding: 45.2M.

  • Trailing P/E: −0.6×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MapLight Therapeutics, Inc. employs 133 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

MPLT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MPLTMapLight Therapeutics, Inc.$519.9M
10
ARVNArvinas, Inc.$601.5M
84
ALTAltimmune, Inc.$604.4M
23
VSTMVerastem, Inc.$605.2M
58
PRMEPrime Medicine, Inc.$614.9M
33
EIKNEikon Therapeutics, Inc.$616.2M
2
OABIOmniAb, Inc.$623.3M
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MapLight Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MPLT news & analysis

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

MapLight Therapeutics reported Q2 2026 financial results and a business update, highlighting positive Phase 2 ZEPHYR data for ML-007C-MA in schizophrenia supporting advancement to a Phase 3 trial, ongoing enrollment in the Phase 2 VISTA trial for ADP, and IRIS results for ML-004 in autism spectrum disorder. The company ended the quarter with $351.3 million in cash, which, along with a $150 million private placement, is expected to fund operations through 2028.

Why it matters — MapLight watchers would care because the positive Phase 2 ZEPHYR results and extended cash runway through 2028 position the company to advance its lead program ML-007C-MA through anticipated readouts for both VISTA and ZEPHYR-2.

MapLight Therapeutics Announces $150 Million Private Placement Financing

GlobeNewsWire · 13 Aug 2026positive

MapLight Therapeutics has entered into a securities purchase agreement for a private placement financing (PIPE) that is expected to generate approximately $150 million in gross proceeds from institutional and accredited investors.

Why it matters — The $150 million PIPE provides MapLight with significant additional capital to fund its clinical-stage development programs for central nervous system disorders, which may extend its financial runway and support ongoing trials.

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

PRNewsWire · 3 Aug 2026negative

Shareholder rights law firm Schall, Brown & Schwartz LLP announced it is investigating claims on behalf of MapLight Therapeutics investors for possible violations of securities laws. The investigation focuses on whether MapLight issued false and/or misleading statements or failed to disclose information pertinent to investors.

Why it matters — An active securities-law investigation raises legal and reputational risk that MPLT investors would want to monitor in the company's news.

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript

Seeking Alpha · 28 July 2026neutral

MapLight Therapeutics discussed the top line results of its Phase 2 ZEPHYR study of ML-007C-MA, a treatment for schizophrenia, in a transcript published by Seeking Alpha.

Why it matters — MPLT watchers would care because the Phase 2 ZEPHYR results are a key milestone for the company's lead pipeline candidate, ML-007C-MA, and could signal the drug's potential trajectory toward regulatory advancement.

Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint

MarketBeat · 27 July 2026positive

Maplight Therapeutics reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen showing a statistically significant improvement in PANSS total scores versus placebo at five weeks.

Why it matters — A positive Phase II readout moves ML-007C-MA closer to potential regulatory filing and reinforces MPLT's position in schizophrenia treatment.

FAQ

Frequently asked questions about MPLT stock

What is the MPLT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering MapLight Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $13 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MPLT stock a buy right now?

Of the 14 analysts covering MapLight Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MapLight Therapeutics, Inc. 10 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MPLT?

As at 22 Aug 2026, MapLight Therapeutics, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (53 of 100).

Will MPLT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +120.1% from the last close, and Ticker Nerd's factor model ranks MapLight Therapeutics, Inc. 10 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MPLT stock forecast for 2030?

No analyst covering MapLight Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MPLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $45 over the next 12 months.

What does MapLight Therapeutics, Inc. do?

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders.

What is the latest news on MPLT?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update". MapLight Therapeutics reported Q2 2026 financial results and a business update, highlighting positive Phase 2 ZEPHYR data for ML-007C-MA in schizophrenia supporting advancement to a Phase 3 trial, ongoing enrollment in the Phase 2 VISTA trial for ADP, and IRIS results for ML-004 in autism spectrum disorder. The company ended the quarter with $351.3 million in cash, which, along with a $150 million private placement, is expected to fund operations through 2028.

Company

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. Its primary focus is on discovering and advancing circuit-specific treatments designed to address severe and difficult-to-treat brain conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease. The company's leading drug candidate, ML-007C-MA, combines M1/M4 muscarinic agonism with a peripherally acting anticholinergic, specifically targeting symptoms of schizophrenia and Alzheimer’s disease-related psychosis. Additional candidates in the pipeline address social deficits in autism, motor issues in Parkinson’s disease, and agitation-related disorders through novel pharmacological approaches. Founded in 2018 by leaders in psychiatry and neuroscience, MapLight Therapeutics leverages a proprietary discovery platform that identifies and modulates neural circuits causally linked to disease, aiming to move beyond the limitations of traditional CNS medications. The company plays a significant role in the ongoing evolution of neuropsychiatric drug development, prioritizing scientific rigor and circuit specificity to potentially offer safer and more effective therapeutic options for underserved patient populations.

CEO Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. · 133 employees · United States · https://www.maplightrx.com